hotspot -WSS

hotspot

author：focus 2025-09-30 01:02:24 - browse：4877

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Venture capital firm's plans to take over Akron hospital face hurdles

WSS

As AI regulations shape up, health tech startups beg for clarity

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Obamacare plans could cover weight loss drugs

Venture capital firm's plans to take over Akron hospital face hurdles

Reporting on presidential health from Reagan to Trump and Biden

hotspot

hotspot

focus

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Biogen walks away from Aduhelm, years after polarizing approval

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Supreme Court strikes down use of affirmative action

Reporting on presidential health from Reagan to Trump and Biden

Cancer drug shortages should be causing more outrage

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

focus

Surprise medical billing ban raises prices elsewhere

Medicare Advantage enrollment hits roughly 33.4 million

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Merck, Johnson & Johnson CEOs will testify on high drug prices

Reconstructing family trees of blood cells may help predict disease

Reconstructing family trees of blood cells may help predict disease

entertainment

focus

Wikipedia

hotspot